Compass Therapeutics Reports the First Patient Dosing of CTX-471 + Keytruda (pembrolizumab) for the Treatment of Advanced Solid Tumors

Published: Dec 02, 2022 | Tags: Compass Therapeutics, CTX-471, Keytruda, pembrolizumab, Advanced Solid Tumors, Clinical Trial

Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

Published: Dec 02, 2022 | Tags: Qilu Pharmaceutical, QL1706, Non-Small Cell Lung Cancer, Clinical Trial, P-II Study, ESMO, 2022

Rigel’s Rezlidhia (olutasidenib) Receives the US FDA’s Approval for the Treatment of Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Published: Dec 02, 2022 | Tags: Rigel, Rezlidhia, olutasidenib, Acute Myeloid Leukemia, IDH1 Mutation, Regulatory, US, FDA, Approval

UroGen Presents P-III (OLYMPUS) Trial Results of Jelmyto (mitomycin) for the Treatment of Low-Grade Upper Tract Urothelial Cancer at SUO 2022

Published: Dec 02, 2022 | Tags: UroGen, Jelmyto, mitomycin, Low-Grade Upper Tract Urothelial Cancer, Clinical Trial, P-III (OLYMPUS) Trial, SUO, 2022

Anavex Presents P-IIb/III (ANAVEX 2-73-AD-004) Trial Results of ANAVEX 2–73 (blarcamesine) for Early Alzheimer’s Disease at CTAD 2022

Published: Dec 02, 2022 | Tags: Anavex, ANAVEX 2–73, blarcamesine, Early Alzheimer’s Disease, Clinical Trial, P-IIb/III (ANAVEX 2-73-AD-004) Trial, CTAD, 2022

SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Published: Dec 02, 2022 | Tags: SCYNEXIS, Brexafemme, ibrexafungerp, Vulvovaginal Candidiasis, Regulatory, US, FDA, Approval

AbCellera Collaborated with Rallybio to Develop and Commercialize Novel Antibody-Based Therapies for the Treatment of Rare Diseases

Published: Dec 01, 2022 | Tags: AbCellera, Rallybio, Antibody-Based Therapies, Rare Diseases, Ab discovery engine, Pharma

IPA’s Subsidiary BioStrand Entered into a Research Collaboration and License Agreement with BriaCell to Discover and Develop Anti-Cancer Antibodies

Published: Dec 01, 2022 | Tags: IPA, BioStrand, BriaCell, Anti-Cancer Antibodies, LENSai software, HYFT Universal Fingerprint technologies

Liminatus Pharma Entered into a Definitive Business Combination Agreement with Iris to Advance the Cancer Treatment

Published: Dec 01, 2022 | Tags: Liminatus Pharma, Iris, colorectal, pancreatic, gastric, esophageal cancers, M&A

Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Evkeeza (evinacumab) to Treat Homozygous Familial Hypercholesterolemia

Published: Dec 01, 2022 | Tags: Regeneron, Evkeeza, evinacumab, Homozygous Familial Hypercholesterolemia, Regulatory, US, FDA, Acceptance, sBLA, Priority Review

BioNTech Entered into a Multi-Target Research Collaboration with Ryvu Therapeutics to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Published: Dec 01, 2022 | Tags: BioNTech, Ryvu Therapeutics, Immuno-Modulatory Small Molecule Candidates, oncology, Pharma

Eli Lilly Reports P-III (TRAILBLAZER-ALZ 4) Study Results of Donanemab for the Treatment of Early Symptomatic Alzheimer's Disease

Published: Dec 01, 2022 | Tags: Eli Lilly, Donanemab, Early Symptomatic Alzheimer's Disease, Clinical Trial, P-III, TRAILBLAZER-ALZ 4 Study

Eisai and Biogen Publishes Results of P-III Study (Clarity AD) of Lecanemab for Early Alzheimer's Disease

Published: Nov 30, 2022 | Tags: Eisai, Biogen, Lecanemab, Early Alzheimer's Disease, Clinical Trial, P-III, New England Journal of Medicine, Clarity AD

Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US

Published: Nov 30, 2022 | Tags: Shanghai Henlius Biotech, Hansizhuang, serplulimab, Extensive-Stage Small Cell Lung Cancer Treatment, MSI-H solid tumors, squamous non-small cell lung cancer, Clinical Trial, NMPA, US FDA, NDA

Turnstone Biologics and National Cancer Institute Enters into a R&D Agreement to Study TIL Therapy + Viral Immunotherapy for Solid Tumors

Published: Nov 30, 2022 | Tags: Turnstone Biologics, National Cancer Institute, TIL Therapy, Immunotherapy, Solid Tumors, Pharma

Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

Published: Nov 30, 2022 | Tags: Autobahn, ABX-002, Major Depressive Disorder, Clinical Trial, P-I

Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China

Published: Nov 30, 2022 | Tags: Aclaris, Pediatrix, ATI-1777, Atopic Dermatitis, Clinical Trials, Greater China

Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

Published: Nov 30, 2022 | Tags: Immutep, Merck KGaA, Pfizer, Eftilagimod Alpha, Avelumab, Urothelial Cancer, Clinical Trial, Germany, INSIGHT-005, INSIGHT-004

CSL Vifor and Fresenius Kabi Receive the NMPA’s Approval for Ferinject to Treat Iron Deficiency in Adult Patients

Published: Nov 29, 2022 | Tags: CSL Vifor, Fresenius Kabi, Ferinject, Iron Deficiency, Regulatory, NMPA Approval

AstraZeneca to Acquire Neogene Therapeutics for ~$320M

Published: Nov 29, 2022 | Tags: AstraZeneca, Neogene Therapeutics, Acquire, ~$320M, solid tumors

Full-Life Technologies Signed an Agreement to Acquire Focus-X Therapeutics to Advance Peptide-Focused Radiopharmaceutical Pipeline

Published: Nov 29, 2022 | Tags: Full-Life Technologies, Focus-X Therapeutics, Peptide-Focused Radiopharmaceutical Pipeline, pancreatic cancer, metastatic castration resistant prostate cancer, M&A

axsome Therapeutics Reports P-III (ACCORD) Trial Results of AXS-05 for the Treatment of Alzheimer’s Disease Agitation

Published: Nov 29, 2022 | Tags: axsome Therapeutics, AXS-05, Alzheimer’s Disease Agitation, Clinical Trial, P-III, ACCORD Trial

Arcutis Reports P-IIb Study Results of Roflumilast for the Treatment of Plaque Psoriasis

Published: Nov 29, 2022 | Tags: Arcutis, Roflumilast Cream, Plaque Psoriasis, Clinical Trial, P-IIb Study

Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

Published: Nov 29, 2022 | Tags: Biocytogen, ADC Therapeutics, Antibody-Based Therapies, Project Integrum, RenMice HiTS Platform, Option Agreement, Biotech

RadNet AI Subsidiary Aidence Collaborated with Google Health to Improve Lung Cancer Screening Using AI Solutions

Published: Nov 28, 2022 | Tags: RadNet, Aidence, Google Health, Lung Cancer, AI Solutions, NELSON trial, Pharma

AstraZeneca Signed ~$402M Exclusive Worldwide License Agreement with C4XD to Develop and Commercialize NRF2 Activator Program

Published: Nov 28, 2022 | Tags: AstraZeneca, C4XD, NRF2 Activator Program, Pharma

GSK Submits Respiratory Syncytial Virus Vaccine for Regulatory Review to Health Canada

Published: Nov 28, 2022 | Tags: GSK, Respiratory Syncytial Virus Vaccine, Regulatory Review, Health Canada, Clinical Trial

Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022

Published: Nov 28, 2022 | Tags: Edwards, EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement, Tricuspid Regurgitation, Clinical Trial, TRISCEND Study

Lyvgen Entered into a Clinical Collaboration with BMS to Evaluate LVGN7409 + Nivolumab for Non-Small Cell Lung Cancer

Published: Nov 28, 2022 | Tags: Lyvgen, BMS, LVGN7409, Nivolumab, Non-Small Cell Lung Cancer, Pharma

BMS’ Opdivo (nivolumab) Receives NICE Recommendation as 1L Treatment for Rare Gastroesophageal Cancers

Published: Nov 28, 2022 | Tags: BMS, Opdivo, nivolumab, Gastroesophageal Cancers, Regulatory, NICE

Related Post: PharmaShots Weekly Snapshots (November 21 - 25, 2022)